Abstract: A method of providing information on or regarding a product in an electronic device according to various example embodiments of the present disclosure may include identifying detailed information on a first product in response to a request on a first page for the first product, identifying, when the first product is included in a specific category, at least one second product corresponding to the specific category, identifying at least one attribute list corresponding to the specific category, and, providing the first page, wherein the first page includes detailed information on the first product displayed in a first portion, first attribute information of the first product corresponding to the attribute list and displayed in a second portion, and second attribute information of the at least one second product corresponding to the attribute list and displayed in a third portion corresponding to the second portion.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes mellitus in an animal of the family Canidae, including enavogliflozin as an active ingredient. The pharmaceutical composition, of the present invention, including enavogliflozin as an active ingredient exhibits an excellent blood glucose level control effect and thus can be effectively used for treating diabetes mellitus in an animal of the family Canidae.

Abstract: The pharmaceutical composition according to the present invention is used at specific therapeutic regimen and dosage, and can be usefully used for the prevention or treatment of fibrosis.

Abstract: A method of providing information on or regarding a product in an electronic device according to various example embodiments of the present disclosure may include identifying detailed information on a first product in response to a request on a first page for the first product, identifying, when the first product is included in a specific category, at least one second product corresponding to the specific category, identifying at least one attribute list corresponding to the specific category, and, providing the first page, wherein the first page includes detailed information on the first product displayed in a first portion, first attribute information of the first product corresponding to the attribute list and displayed in a second portion, and second attribute information of the at least one second product corresponding to the attribute list and displayed in a third portion corresponding to the second portion.

Abstract: A method of providing information on or regarding a product in an electronic device according to various example embodiments of the present disclosure may include identifying detailed information on a first product in response to a request on a first page for the first product, identifying, when the first product is included in a specific category, at least one second product corresponding to the specific category, identifying at least one attribute list corresponding to the specific category, and, providing the first page, wherein the first page includes detailed information on the first product displayed in a first portion, first attribute information of the first product corresponding to the attribute list and displayed in a second portion, and second attribute information of the at least one second product corresponding to the attribute list and displayed in a third portion corresponding to the second portion.

Abstract: A method of providing information on or regarding a product in an electronic device according to various example embodiments of the present disclosure may include identifying detailed information on a first product in response to a request on a first page for the first product, identifying, when the first product is included in a specific category, at least one second product corresponding to the specific category, identifying at least one attribute list corresponding to the specific category, and, providing the first page, wherein the first page includes detailed information on the first product displayed in a first portion, first attribute information of the first product corresponding to the attribute list and displayed in a second portion, and second attribute information of the at least one second product corresponding to the attribute list and displayed in a third portion corresponding to the second portion.

Abstract: The present invention relates to a UV-curable hydrogel resin for transdermal administration, a hydrogel prepared using the UV-curable hydrogel resin, and a cataplasm prepared using the UV-curable hydrogel resin. More particularly, the present invention relates to a hydrogel resin with an optimal composition and composition ratio which allows increase in a water content of a hydrogel applied as a drug layer of a cataplasm, skin irritation mitigation, and crosslinking degree adjustment for adhesion control and is capable of controlling drug releasing property and transdermal absorbability, a hydrogel prepared by UV-hardening the hydrogel resin, and a cataplasm including the hydrogel.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating myositis. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from myositis, inflammatory cells infiltrated into the muscle cells of the subject can be reduced. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of IL-1?, TNF-?, and IL-6, inflammatory cytokines. Therefore, the pharmaceutical composition according to the present invention can be usefully used for preventing or treating myositis.

Abstract: The present invention relates to a pharmaceutical composition for the treatment of sepsis or systemic inflammatory response syndrome (SIRS) comprising mitochondria as effective ingredient. When activated macrophages and monocytes are treated with mitochondria which are effective ingredient of the pharmaceutical composition of the present invention, expression of IL-1?, TNF-? and IL-6 which are pro-inflammatory cytokines can be restored to normal levels. Furthermore, when the pharmaceutical composition of the present invention is administered to a subject suffering from sepsis, the survival rate of the subject can be remarkably increased. Therefore, the pharmaceutical composition according to the present invention can be useful for the treatment of sepsis.

Abstract: A display panel inspecting apparatus includes a first inspecting transistor including a control electrode for receiving a first test gate signal, an input electrode for receiving a first voltage and an output electrode connected to an outermost data line disposed in an outermost area of a display region of a display panel, a second inspecting transistor including a control electrode for receiving the first test gate signal, an input electrode for receiving a second voltage and an output electrode connected to a normal data line disposed out of the outermost area of the display region, and a third inspecting transistor including a control electrode for receiving the first test gate signal, an input electrode for receiving a third voltage and an output electrode connected to a module crack inspecting data line disposed out of the outermost area of the display region.

Abstract: A display cover substrate according to an embodiment includes: a flexible substrate including one surface and the other surface opposite to the one surface; a surface reinforcing layer disposed on the one surface; and a functional layer disposed on the surface reinforcing layer, wherein the functional layer includes a plurality of layers having different refractive indexes, and an average light transmittance is 90% or more in a light wavelength band of 388 nm to 700 nm, and an average light transmittance is less than 90% and a minimum light transmittance is 60% or less in a light wavelength band of 250 nm to 388 nm.

Abstract: A display panel inspecting apparatus includes a first inspecting transistor including a control electrode for receiving a first test gate signal, an input electrode for receiving a first voltage and an output electrode connected to an outermost data line disposed in an outermost area of a display region of a display panel, a second inspecting transistor including a control electrode for receiving the first test gate signal, an input electrode for receiving a second voltage and an output electrode connected to a normal data line disposed out of the outermost area of the display region, and a third inspecting transistor including a control electrode for receiving the first test gate signal, an input electrode for receiving a third voltage and an output electrode connected to a module crack inspecting data line disposed out of the outermost area of the display region.

Abstract: A camera module includes a lens module including a lens barrel and a holder to hold the lens barrel, a heater to seal the lens module and including a first cutting portion having a D-shape, and a ring-shaped electrode portion including a second cutting portion having a D-shape and a third cutting portion having a D-shape. The electrode portion is coupled to two surfaces of the heater that are perpendicular to an optical axis direction to align the first cutting portion with the second cutting portion and the third cutting portion.

Abstract: A display cover substrate according to an embodiment includes: a flexible substrate including one surface and the other surface opposite to the one surface; a surface reinforcing layer disposed on the one surface; and a functional layer disposed on the surface reinforcing layer, wherein the functional layer includes a plurality of layers having different refractive indexes, and an average light transmittance is 90% or more in a light wavelength band of 388 nm to 700 nm, and an average light transmittance is less than 90% and a minimum light transmittance is 60% or less in a light wavelength band of 250 nm to 388 nm.

Abstract: A camera module includes a lens module including a lens barrel and a holder to hold the lens barrel, a heater to seal the lens module and including a first cutting portion having a D-shape, and a ring-shaped electrode portion including a second cutting portion having a D-shape and a third cutting portion having a D-shape. The electrode portion is coupled to two surfaces of the heater that are perpendicular to an optical axis direction to align the first cutting portion with the second cutting portion and the third cutting portion.

Abstract: The present invention relates to a UV-curable hydrogel resin for transdermal administration, a hydrogel prepared using the UV-curable hydrogel resin, and a cataplasm prepared using the UV-curable hydrogel resin. More particularly, the present invention relates to a hydrogel resin with an optimal composition and composition ratio which allows increase in a water content of a hydrogel applied as a drug layer of a cataplasm, skin irritation mitigation, and crosslinking degree adjustment for adhesion control and is capable of controlling drug releasing property and transdermal absorbability, a hydrogel prepared by UV-hardening the hydrogel resin, and a cataplasm including the hydrogel.

Abstract: A novel anti-vascular endothelial growth factor (VEGF) antibody having a strong binding affinity for VEGF and capable of inhibiting in vivo tumor growth and a composition for the treatment of cancer, containing the same. The antibody shows a remarkable binding property to human and mouse VEGF, suppresses the proliferation and permeability of a human umbilical vein endothelial cell (HUVEC) and inhibits tumor growth, and thus can be useful as an antibody for the treatment of cancer.

Abstract: A compound selected from the group consisting of an isoquinoline-5-carboxamide derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate and a solvate thereof is effective for the prevention or treatment of diseases associated with abnormal cell growth, which are caused by abnormal activation of a protein kinases.

Abstract: A novel anti-vascular endothelial growth factor (VEGF) antibody having a strong binding affinity for VEGF and capable of inhibiting in vivo tumor growth and a composition for the treatment of cancer, containing the same. The antibody shows a remarkable binding property to human and mouse VEGF, suppresses the proliferation and permeability of a human umbilical vein endothelial cell (HUVEC) and inhibits tumor growth, and thus can be useful as an antibody for the treatment of cancer.

Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.